CSTONE PHARMA-B (02616) Surges Over 20% on Strong CS2009 Lung Cancer Efficacy Data; First Phase III Global Trials Expected This Year

Stock News11:32

CSTONE PHARMA-B (02616) saw its gains expand beyond 20%. At the time of writing, the stock was up 19.42% to HK$8.24, with a turnover of HK$377 million. The surge follows the company's announcement of the latest clinical progress for its self-developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. Preliminary efficacy data from Phase I/II trials of CS2009 as a monotherapy for lung cancer showed promising results. Among first-line non-small cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) of 50% or higher, the objective response rate (ORR) reached 90%, with a disease control rate (DCR) of 100%. In immunotherapy (IO) pretreated, driver gene-negative second-line and later-line NSCLC patients, the ORR was 25%. Based on these outcomes, CSTONE PHARMA-B plans to initiate the first set of Phase III global multicenter clinical trials (MRCT) for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). Additional Phase I and II clinical research data for CS2009 are expected to be presented in 2026 at the American Society of Clinical Oncology (ASCO) annual meeting and/or the European Society for Medical Oncology (ESMO) congress.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184614767?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184614767","market":"fut","top_or_hot":-1,"title":"CSTONE PHARMA-B (02616) Surges Over 20% on Strong CS2009 Lung Cancer Efficacy Data; First Phase III Global Trials Expected This Year","media":"Stock News","content":"<p>CSTONE PHARMA-B (02616) saw its gains expand beyond 20%. At the time of writing, the stock was up 19.42% to HK$8.24, with a turnover of HK$377 million. The surge follows the company's announcement of the latest clinical progress for its self-developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. Preliminary efficacy data from Phase I/II trials of CS2009 as a monotherapy for lung cancer showed promising results. Among first-line non-small cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) of 50% or higher, the objective response rate (ORR) reached 90%, with a disease control rate (DCR) of 100%. In immunotherapy (IO) pretreated, driver gene-negative second-line and later-line NSCLC patients, the ORR was 25%. Based on these outcomes, CSTONE PHARMA-B plans to initiate the first set of Phase III global multicenter clinical trials (MRCT) for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). Additional Phase I and II clinical research data for CS2009 are expected to be presented in 2026 at the American Society of Clinical Oncology (ASCO) annual meeting and/or the European Society for Medical Oncology (ESMO) congress.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSTONE PHARMA-B (02616) Surges Over 20% on Strong CS2009 Lung Cancer Efficacy Data; First Phase III Global Trials Expected This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSTONE PHARMA-B (02616) Surges Over 20% on Strong CS2009 Lung Cancer Efficacy Data; First Phase III Global Trials Expected This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-27 11:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B (02616) saw its gains expand beyond 20%. At the time of writing, the stock was up 19.42% to HK$8.24, with a turnover of HK$377 million. The surge follows the company's announcement of the latest clinical progress for its self-developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. Preliminary efficacy data from Phase I/II trials of CS2009 as a monotherapy for lung cancer showed promising results. Among first-line non-small cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) of 50% or higher, the objective response rate (ORR) reached 90%, with a disease control rate (DCR) of 100%. In immunotherapy (IO) pretreated, driver gene-negative second-line and later-line NSCLC patients, the ORR was 25%. Based on these outcomes, CSTONE PHARMA-B plans to initiate the first set of Phase III global multicenter clinical trials (MRCT) for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). Additional Phase I and II clinical research data for CS2009 are expected to be presented in 2026 at the American Society of Clinical Oncology (ASCO) annual meeting and/or the European Society for Medical Oncology (ESMO) congress.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1184614767","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184614767","pubTimestamp":1774582341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSTONE PHARMA-B (02616) saw its gains expand beyond 20%. At the time of writing, the stock was up 19.42% to HK$8.24, with a turnover of HK$377 million. The surge follows the company's announcement of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","02616":"基石药业-B","VXUS":"国际股票ETF-Vanguard","BK4134":"信息科技咨询与其它服务","III":"信息服务","BK4588":"碎股","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"基石药业-B(02616)因CS2009肺癌疗效数据强劲而飙升逾20%；首个III期全球试验预计今年进行","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"02616":1,"VXUS":1},"content_text":"CSTONE PHARMA-B (02616) saw its gains expand beyond 20%. At the time of writing, the stock was up 19.42% to HK$8.24, with a turnover of HK$377 million. The surge follows the company's announcement of the latest clinical progress for its self-developed PD-1/VEGF/CTLA-4 trispecific antibody, CS2009. Preliminary efficacy data from Phase I/II trials of CS2009 as a monotherapy for lung cancer showed promising results. Among first-line non-small cell lung cancer (NSCLC) patients with a PD-L1 tumor proportion score (TPS) of 50% or higher, the objective response rate (ORR) reached 90%, with a disease control rate (DCR) of 100%. In immunotherapy (IO) pretreated, driver gene-negative second-line and later-line NSCLC patients, the ORR was 25%. Based on these outcomes, CSTONE PHARMA-B plans to initiate the first set of Phase III global multicenter clinical trials (MRCT) for CS2009 by the end of 2026, focusing on indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). Additional Phase I and II clinical research data for CS2009 are expected to be presented in 2026 at the American Society of Clinical Oncology (ASCO) annual meeting and/or the European Society for Medical Oncology (ESMO) congress.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184614767","isCrawlerRequest":true}